



NDA 20667/S-030

SUPPLEMENT APPROVAL

Boehringer Ingelheim Pharmaceuticals, Inc.
Attention: Steven Berthel, Ph.D.,
Associate Director, Regulatory Affairs
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877

Dear Dr. Berthel:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 29, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mirapex (Pramipexole Dihydrochloride) Oral Tablet: 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, and 1.5mg.

This "Prior Approval" supplemental new drug application proposes the following updates to the Mirapex Prescribing Information:

Highlights

- edits to "Recent Major Changes"

Dosage and Administration (section 2.2)

- edits regarding discontinuation of treatment to provide for consistency with the recommendations in the recently approved Mirapex ER Prescribing Information

Clinical Pharmacology (section 12.2)

- edits regarding dose titration to provide for consistency with the recommendations in the recently approved Mirapex ER Prescribing Information

Patient Counseling Information (section 17)

- removal of numbers for subsections,
- change of passive voice to active voice, and
- correction of the wording of the reference statement for FDA-approved patient labeling

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tracy Peters, PharmD, Senior Regulatory Project Manager, at (301) 796-2953.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
03/27/2015